Results 21 to 30 of about 31,918 (237)

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil

World Journal of Surgical Oncology, 2019
Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high.
Yu Ohkura, Masaki Ueno, Harushi Udagawa
doaj   +1 more source

Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer

South Asian Journal of Cancer, 2020
Introduction: Breast cancer is the most frequently diagnosed cancer among the women. Most commonly used chemotherapy regimen is Doxorubicin and Cyclophosphamide (AC) which carries significant risk of febrile neutropenia.
Nageswara Reddy Palukuri, Rajani Priya Yedla, Stalin Chowdary Bala, Siva Prasad Kuruva, Rachana Chennamaneni, Meher Lakshmi Konatam, Sadashivudu Gundeti   +6 more
doaj   +1 more source

Adult Patient Care Plan: Management of the Febrile Neutropenic Cancer Patient on an Outpatient Basis

Canadian Journal of Infectious Diseases, 2000
Invasive infection may complicate the course of neutropenic cancer patients receiving intensive chemotherapy. The rate of complications is related to prognostic factors including the underlying malignant diagnosis, the state of responsiveness of the ...
Coleman Rotstein, Eric J Bow, The Febrile Neutropenia Care Plan Working Group   +2 more
doaj   +1 more source

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

Biology, 2021
Background: The aim of this review and meta-analysis was to identify, assess, meta-analyze and summarize the comparative effectiveness and safety of filgrastim in head-to-head trials with placebo/no treatment, pegfilgrastim (and biosimilar filgrastim to ...
Shruti Rastogi, Vivekananda Kalaiselvan, Sher Ali, Ajaz Ahmad, Sameer Ahmad Guru, Maryam Sarwat   +5 more
doaj   +1 more source

Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting

Balkan Medical Journal, 2017
Background: Haematopoietic stem cell transplantation is a curative treatment option for many haematological disorders. Infection following haematopoietic stem cell transplantation is one of the major causes of mortality.
Ali Hakan Kaya, Emre Tekgündüz, Fazilet Duygu, Dicle Koca, Filiz Bekdemir, Hikmetullah Batgi, Bahar Ulu Uncu, Tuğçe Nur Yiğenoğlu, Mehmet Sinan Dal, Merih Çakar Kızıl, Fevzi Altuntaş   +10 more
doaj   +1 more source

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)

Frontiers in Oncology, 2023
IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as
Ga-Young Song, Je-Jung Lee, Joon Ho Moon, Dajung Kim, Min Kyoung Kim, Hyo Jung Kim, Yeung-Chul Mun, Won-Sik Lee, Young Rok Do, Jae Hoon Lee, Sung-Hoon Jung, Jin Seok Kim   +11 more
doaj   +1 more source

Antimicrobial de-escalation in patients with high-risk febrile neutropenia: Attitudes and practices of adult hospital care providers

Antimicrobial Stewardship & Healthcare Epidemiology, 2021
In a survey of adult hospital providers regarding antibiotic use in the treatment of febrile neutropenia, clinical fellows, and pharmacists showed higher comfort levels with early antimicrobial de-escalation compared to hematology-oncology and transplant
Chelsea A. Gorsline, Milner B. Staub, George E. Nelson, Whitney J. Nesbitt, Bhagirathbhai R. Dholaria, Gowri Satyanarayana   +5 more
doaj   +1 more source

Febrile neutropenia in chemotherapy treated small-cell lung cancer patients

Radiology and Oncology, 2015
Background. Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrile neutropenia.
Kukec Renata Rezonja, Grabnar Iztok, Vovk Tomaz, Mrhar Ales, Kovac Viljem, Cufer Tanja   +5 more
doaj   +1 more source

Epidemiology and source of infection in patients with febrile neutropenia: A ten-year longitudinal study

Journal of Infection and Public Health, 2019
Objectives: No recent studies are available from Saudi Arabia on the etiology of febrile neutropenia. The objective of this study was to describe the characteristics of patients with febrile neutropenia and to calculate the rate of occurrence of ...
Jaffar A. Al-Tawfiq, Kareem Hinedi, Hanan Khairallah, Bassam Saadeh, Suhail Abbasi, Madeeha Noureen, Safia Raza, Adil Alkhatti   +7 more
doaj   +1 more source

Level of Knowledge and Incidence of Emergency Oncology: Febrile Neutropenia in Hematologic Cancer Patients Post Chemotherapy: A Descriptive Study

Masker Medika
Introduction: Febrile neutropenia is a life-threatening condition that is the most common oncological emergency, especially in cases of hematological cancer. Knowledge related to this condition can accelerate treatment and reduce mortality. The danger of
Agus Suryaman
doaj   +1 more source